ABBV/ENTA’s Global Phase-3 Program for ABT-493/ABT-530
[Updated for start of EXPEDITION-4 study.]
There are six phase-3 trials with a total of 1,600 patients and 250 clinical-trial sites in 27 countries; all of these trials are expected to report data in 2016 or Jan 2017.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.